& CEIFX
Good day, 360!
HEADS UP: JW is having an Open House TODAY in Market Navigator – join him as he’s added his own Pick of the Week to his flagship SPY trading service ($29 trial ends Monday).
Be the best prepared trader on the Streeeeettttt!
FOCUS LIST🔎
TAOP – Up over 130% in the pre-market after receiving Nasdaq minimum bid price requirement extension
FRSX – Up over 48% in pre after announcing partnership with SoftBank to join forces with Japanese automaker to advance Cellular V2X technology for enhanced road safety
HUMA – Up over 50% in pre after announcing FDA approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma
Solving a Silent Threat to Your Health
Chemical pesticides are being used in our food, homes and offices. But Med-X has developed a 100% chemical-free pesticide proven to outperform traditional solutions in mosquito control. For a limited time, you can become a shareholder as they expand to 41 new global markets.
HOTLIST🔥
TAOP – Up over 130% in the pre-market after receiving Nasdaq minimum bid price requirement extension
Taoping Inc. (TAOP) provides cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China.
In the pre-market this morning, the company announcedthat on December 19, 2024, it received notification from The Nasdaq Stock Market LLC confirming the Company has been granted an additional 180 calendar day period for compliance under its minimum bid price requirement through June 16, 2025.
To regain compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5810(c)(3)(A), the closing bid price of the Company’s ordinary shares needs to be at least US$1.00 per share or greater for at least ten consecutive business days by June 16, 2025.
The Company intends to monitor the closing bid price of the ordinary shares and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Shares of TAOP traded up over 130% in the pre-market in reaction to the news.
The $0.69 area acted as resistance and then support and will be an important level to watch.
Above it, targets to the upside are $0.85, $0.95 and then the pre-market high at $1.05. Beyond that, $1.20, $1.38 and $1.50 come into play.
Below $0.69, targets to the downside are $0.55, $0.50, $0.43 and then a gap fill at $0.3170.
FRSX – Up over 48% in pre after announcing partnership with SoftBank to join forces with Japanese automaker to advance Cellular V2X technology for enhanced road safety
Foresight Autonomous Holdings Ltd. (FRSX) is a technology company that engages in the development of smart multi-spectral 3D vision software solutions and cellular-based applications for the automotive industry in Israel, Japan, the United States, and internationally.
In the pre-market this morning, the company announcedthat its wholly owned subsidiary, Eye-Net Mobile Ltd. has entered into a multi-phase agreement with SoftBank Corp. (Tokyo: 9434) and a leading Japanese vehicle manufacturer.
The collaboration aims to evaluate Eye-Net’s cutting-edge cellular vehicle-to-everything (C-V2X) technology as a key component in advanced driver assistance systems, potentially setting a new standard for road safety.
Under the terms of the agreement signed earlier this year, Eye-Net is conducting a paid proof of concept (POC) project supported by SoftBank’s cellular network infrastructure. This initiative is designed to explore the integration of Eye-Net’s non-line-of-sight collision avoidance solution into the automaker’s future vehicle systems, addressing critical challenges in real-time situational awareness.
Shares of FRSX traded up over 48% in the pre-market in reaction to the news.
The $1.05 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $1.28, $1.42, and then the pre-market high at $2.28.
Below $1.05, targets to the downside are a gap fill at $0.92, with $0.7916, $0.74 and $0.64 below that.
*sponsored by CEIFX
Order Currency Online and Get It As Soon As The Next Day.
Planning your next international trip? Skip the hassle of bank visits and get your foreign currency delivered straight to your home. Traveling with cash ensures you never miss out when traveling. Order today to take advantage of today’s great rates so you can enjoy all your trip has to offer.
HUMA – Up over 50% in pre after announcing FDA approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma
Humacyte, Inc. (HUMA) is a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.
Overnight, the company announcedthat the U.S. Food and Drug Administration (FDA) has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.
Shares of HUMA traded up over 50% in the pre-market in reaction to the news.
The first target for bulls is resistance at $5.82, $6.43 and then the pre-market high at $6.64. Beyond that, $7.05 and $7.50 come into play.
Targets to the downside are $4.95, $4.65, $4.50, $4.10 and then a gap fill at $3.46.
MARKET NEWS 📰
Did You See This Alert Dec 18th –
DAY OF TOTAL MARKET CARNAGE???
(It closed up @ 28% on the day)
Get on our SMS list for our next top target
Simply text “RAGE” to 1-(888) 404-5747 📲
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
